Agilon Health Inc. (AGL) Tops Q2 EPS by 96c ; Offers Guidance

Agilon Health Inc. (NYSE: AGL) reported Q2 EPS of $1.04, $0.96 better than the analyst estimate of $0.08. Revenue for the quarter came in at $1.49 billion versus the consensus estimate of $1.44 billion.

GUIDANCE:

Agilon Health Inc. sees Q3 2026 revenue of $1.44-1.47 billion, versus the consensus of $1.41 billion.

For earnings history and earnings-related data on Agilon Health Inc. (AGL) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Morgan Stanley Upgrades Coloplast A/S (COLOB:DC) (CLPBY) to Equalweight
• Morgan Stanley Starts Carl Zeiss Meditec AG (AFX:GR) (CZMWY) at Underweight